<SEC-DOCUMENT>0001104659-25-017621.txt : 20250226
<SEC-HEADER>0001104659-25-017621.hdr.sgml : 20250226
<ACCEPTANCE-DATETIME>20250226192954
ACCESSION NUMBER:		0001104659-25-017621
CONFORMED SUBMISSION TYPE:	4
PUBLIC DOCUMENT COUNT:		1
CONFORMED PERIOD OF REPORT:	20250224
FILED AS OF DATE:		20250226
DATE AS OF CHANGE:		20250226

REPORTING-OWNER:	

	OWNER DATA:	
		COMPANY CONFORMED NAME:			Capponi Vincent
		CENTRAL INDEX KEY:			0001368151
		ORGANIZATION NAME:           	

	FILING VALUES:
		FORM TYPE:		4
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-36792
		FILM NUMBER:		25672182

	MAIL ADDRESS:	
		STREET 1:		MEDASORB TECHNOLOGIES
		STREET 2:		7 DEER PARK DRIVE, SUITE K
		CITY:			MONMOUTH JUNCTION
		STATE:			NJ
		ZIP:			08852

ISSUER:		

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Cytosorbents Corp
		CENTRAL INDEX KEY:			0001175151
		STANDARD INDUSTRIAL CLASSIFICATION:	SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841]
		ORGANIZATION NAME:           	08 Industrial Applications and Services
		IRS NUMBER:				980373793
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	BUSINESS ADDRESS:	
		STREET 1:		305 COLLEGE ROAD EAST
		CITY:			PRINCETON
		STATE:			NJ
		ZIP:			08540
		BUSINESS PHONE:		973-329-8885

	MAIL ADDRESS:	
		STREET 1:		305 COLLEGE ROAD EAST
		CITY:			PRINCETON
		STATE:			NJ
		ZIP:			08540

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	MedaSorb Technologies CORP
		DATE OF NAME CHANGE:	20060807

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	GILDER ENTERPRISES INC
		DATE OF NAME CHANGE:	20020611
</SEC-HEADER>
<DOCUMENT>
<TYPE>4
<SEQUENCE>1
<FILENAME>tm257709-4_4seq1.xml
<DESCRIPTION>OWNERSHIP DOCUMENT
<TEXT>
<XML>
<?xml version="1.0"?>
<ownershipDocument>

    <schemaVersion>X0508</schemaVersion>

    <documentType>4</documentType>

    <periodOfReport>2025-02-24</periodOfReport>

    <notSubjectToSection16>0</notSubjectToSection16>

    <issuer>
        <issuerCik>0001175151</issuerCik>
        <issuerName>Cytosorbents Corp</issuerName>
        <issuerTradingSymbol>CTSO</issuerTradingSymbol>
    </issuer>

    <reportingOwner>
        <reportingOwnerId>
            <rptOwnerCik>0001368151</rptOwnerCik>
            <rptOwnerName>Capponi Vincent</rptOwnerName>
        </reportingOwnerId>
        <reportingOwnerAddress>
            <rptOwnerStreet1>C/O CYTOSORBENTS CORPORATION</rptOwnerStreet1>
            <rptOwnerStreet2>305 COLLEGE ROAD EAST</rptOwnerStreet2>
            <rptOwnerCity>PRINCETON</rptOwnerCity>
            <rptOwnerState>NJ</rptOwnerState>
            <rptOwnerZipCode>08540</rptOwnerZipCode>
            <rptOwnerStateDescription></rptOwnerStateDescription>
        </reportingOwnerAddress>
        <reportingOwnerRelationship>
            <isDirector>0</isDirector>
            <isOfficer>1</isOfficer>
            <isTenPercentOwner>0</isTenPercentOwner>
            <isOther>0</isOther>
            <officerTitle>President and COO</officerTitle>
            <otherText></otherText>
        </reportingOwnerRelationship>
    </reportingOwner>

    <aff10b5One>0</aff10b5One>

    <nonDerivativeTable>
        <nonDerivativeTransaction>
            <securityTitle>
                <value>Common Stock</value>
                <footnoteId id="F1"/>
            </securityTitle>
            <transactionDate>
                <value>2025-02-24</value>
            </transactionDate>
            <deemedExecutionDate></deemedExecutionDate>
            <transactionCoding>
                <transactionFormType>4</transactionFormType>
                <transactionCode>O</transactionCode>
                <equitySwapInvolved>0</equitySwapInvolved>
            </transactionCoding>
            <transactionTimeliness></transactionTimeliness>
            <transactionAmounts>
                <transactionShares>
                    <value>12000</value>
                </transactionShares>
                <transactionPricePerShare>
                    <value>1.13</value>
                    <footnoteId id="F2"/>
                </transactionPricePerShare>
                <transactionAcquiredDisposedCode>
                    <value>A</value>
                </transactionAcquiredDisposedCode>
            </transactionAmounts>
            <postTransactionAmounts>
                <sharesOwnedFollowingTransaction>
                    <value>677168</value>
                    <footnoteId id="F3"/>
                    <footnoteId id="F4"/>
                    <footnoteId id="F5"/>
                </sharesOwnedFollowingTransaction>
            </postTransactionAmounts>
            <ownershipNature>
                <directOrIndirectOwnership>
                    <value>D</value>
                </directOrIndirectOwnership>
            </ownershipNature>
        </nonDerivativeTransaction>
    </nonDerivativeTable>

    <derivativeTable>
        <derivativeTransaction>
            <securityTitle>
                <value>Series A Right Warrants (right to buy)</value>
                <footnoteId id="F1"/>
            </securityTitle>
            <conversionOrExercisePrice>
                <value>1.13</value>
                <footnoteId id="F2"/>
            </conversionOrExercisePrice>
            <transactionDate>
                <value>2025-02-24</value>
            </transactionDate>
            <deemedExecutionDate></deemedExecutionDate>
            <transactionCoding>
                <transactionFormType>4</transactionFormType>
                <transactionCode>O</transactionCode>
                <equitySwapInvolved>0</equitySwapInvolved>
            </transactionCoding>
            <transactionTimeliness></transactionTimeliness>
            <transactionAmounts>
                <transactionShares>
                    <value>12000</value>
                </transactionShares>
                <transactionPricePerShare>
                    <value>1.13</value>
                </transactionPricePerShare>
                <transactionAcquiredDisposedCode>
                    <value>D</value>
                </transactionAcquiredDisposedCode>
            </transactionAmounts>
            <exerciseDate>
                <value>2025-01-17</value>
            </exerciseDate>
            <expirationDate>
                <value>2025-02-24</value>
            </expirationDate>
            <underlyingSecurity>
                <underlyingSecurityTitle>
                    <value>Common Stock</value>
                </underlyingSecurityTitle>
                <underlyingSecurityShares>
                    <value>12000</value>
                </underlyingSecurityShares>
            </underlyingSecurity>
            <postTransactionAmounts>
                <sharesOwnedFollowingTransaction>
                    <value>0</value>
                    <footnoteId id="F6"/>
                </sharesOwnedFollowingTransaction>
            </postTransactionAmounts>
            <ownershipNature>
                <directOrIndirectOwnership>
                    <value>D</value>
                </directOrIndirectOwnership>
            </ownershipNature>
        </derivativeTransaction>
    </derivativeTable>

    <footnotes>
        <footnote id="F1">On January 17, 2025, the Reporting Person exercised certain subscription rights certificates received pursuant to a rights offering (the &quot;Rights Offering&quot;) with CytoSorbents Corporation (the &quot;Issuer&quot;) whereby the Reporting Person received Units consisting of an aggregate of 31,760 (i) shares of Issuer's common stock, par value $0.001 per share (the &quot;Common Stock&quot;), (ii) Series A Warrants to purchase one share of Common Stock, and (iii) Series B Warrants to purchase one share of Common Stock, at a subscription purchase price of $1.00 per unit for an aggregate cost of $31,760. The Rights Offering closed on January 10, 2025 (the &quot;Closing Date&quot;).</footnote>
        <footnote id="F2">The Series A Right Warrants exercise price was calculated as 90% of the 5-day volume weighted average price of the Issuer's Common Stock over the 5-trading days prior to the expiration date of the Series A Right Warrants, rounded down to the nearest whole cent but (x) not lower than $1.00 and (y) not higher than $2.00.</footnote>
        <footnote id="F3">Includes: (i) the following RSUs, which vest as to two-thirds of the award on the first year anniversary of the date of grant and one-third of the award on the second year anniversary of the date of grant, subject to the Reporting Person's continued service as of the applicable vesting date) and will settle into shares of common stock, par value $0.001 per share (the &quot;Common Stock&quot;), of the Company upon vesting: 73,000 RSUs granted on July 7, 2023 and of which 24,334 RSUs remain unvested as of the date hereof;</footnote>
        <footnote id="F4">(continued from footnote 3) (ii) the following RSUs that will be settled into Common Stock upon vesting upon a &quot;Change In Control&quot; of the Company as defined in the Amended and Restated CytoSorbents Corporation 2014 Long-Term Incentive Plan (the &quot;Plan&quot;): (a) 10,100 RSUs granted on March 15, 2018, (b) 17,900 RSUs granted on February 24, 2017, (c) 54,000 RSUs granted on June 7, 2016 and (d) 125,000 RSUs granted on April 8, 2015;</footnote>
        <footnote id="F5">(continued from footnote 4) (iii) the following RSUs, which vest in equal parts on the first year anniversary of the date of grant and the second year anniversary of the date of grant, subject to the Reporting Person's continued service as of the applicable vesting date, and will settle into shares of Common Stock of the Company upon vesting: 81,000 RSUs granted on April 2, 2024 and remain unvested as of the date hereof; and 5. (continued from footnote 4) (iv) 364,834 shares of Common Stock owned by the Reporting Person.</footnote>
        <footnote id="F6">The Reporting Person's remaining 19,760 Series A Warrants expired unexercised on February 24, 2025.</footnote>
    </footnotes>

    <ownerSignature>
        <signatureName>/s/ Vincent Capponi</signatureName>
        <signatureDate>2025-02-26</signatureDate>
    </ownerSignature>
</ownershipDocument>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
